GLP-1 Agonists May Lower Reduce Atrial Fibrillation Recurrence Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention primarily for their benefits in treating type 2 diabetes and supporting weight loss. However, emerging research indicates that these medications may offer additional cardiovascular benefits beyond glucose control and weight reduction. One area of increasing interest is the potential … Continue reading GLP-1 Agonists May Lower Reduce Atrial Fibrillation Recurrence